Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-09-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
关于公司干扰素生产车间被认定为“2024年（第一批）北京市数字化车间”的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the recognition of its interferon production workshop as a '2024 (first batch) Beijing Digital Workshop.' It includes a statement from the board ensuring the accuracy of the announcement, describes the impact of this recognition on the company, and provides a risk warning. There are no financial statements, no detailed financial data, no mention of annual or quarterly results, no voting results, no management changes, no legal proceedings, no capital changes, and no mention of any report being attached or published. The document is an operational update or recognition announcement related to the company's production facilities and digital transformation efforts. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings that require financial or regulatory content. It is not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-25 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details a performance explanation meeting held on September 4, 2024, with extensive Q&A about the company's half-year financial performance, project progress, and strategic initiatives. The content is a transcript or record of an investor relations event focused on explaining financial results and business updates, typical of an earnings or performance explanation meeting. The document length is 4100 characters, which is relatively short and consistent with a meeting record rather than a full financial report. It is not a formal earnings release (ER) since it contains detailed Q&A and discussion rather than just key highlights. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Proxy Statement, Board change, or other categories. The best fit is a Call Transcript (CT) or similar investor meeting transcript. Given the nature of the document as a performance explanation meeting record with Q&A, the most appropriate classification is Call Transcript (CT).
2024-09-05 Chinese
第三届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the review and approval of the company's 2024 semi-annual report and a special report on the use of raised funds. It includes details about the meeting, voting results, and compliance with regulatory requirements. The document does not contain the actual semi-annual financial report but rather the Supervisory Board's approval and opinions on it. The document length is short (1539 characters) and it references the actual semi-annual report being disclosed elsewhere (on the Beijing Stock Exchange website). Therefore, this document is an announcement of the Supervisory Board's resolution related to the interim report, not the interim report itself. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement that does not contain substantive financial data or the full report itself.
2024-08-25 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "半年度报告 2024" which translates to "2024 Semi-Annual Report." It contains detailed financial data such as revenue, profit, cash flow, and asset information for the period January 1, 2024 to June 30, 2024. It includes sections on company overview, accounting data, business summary, risk factors, and detailed operational and financial performance metrics. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and management discussion of results for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is an annual report (10-K) or just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-25 Chinese
2023年度社会责任报告
Regulatory Filings
2024-08-25 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the status of raised funds (募集资金存放与实际使用情况的专项报告) by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the amount of funds raised through a public stock issuance, the usage and balance of these funds up to June 30, 2024, and compliance with regulatory requirements. It includes detailed tables on fund usage, management, and approvals by the board and auditors. The content focuses exclusively on the management and actual use of capital raised from a financing event, rather than a full annual or interim financial report, earnings release, or other types of filings. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP.
2024-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.